Showing 241-250 of 8690 results for "".
Improving Outcomes with Neuromodulators
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/improving-outcomes-with-neuromodulators/18521/Joel L. Cohen, MD offers treatment tips for best, natural outcomes with neuromodulator injections. He also discusses how injecting toxins prior to resurfacing or prior to filler injections can improve results and duration of effects.Neurotoxin Tips and Trends
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/neurotoxin-tips-and-trends/18743/The latest trends in aesthetic dermatology call for a more natural look. Dr. Rossi says dermatologists are injecting less units of neurotoxins, more strategically placed for a more cosmetically pleasing look. He stresses the need to think about neuromodulation rather than paralyzing the muscles to aDerm Insider: Navigating Office Politics
https://practicaldermatology.com/topics/practice-management/derm-insider-navigating-office-politics/18993/In this edition of Derm Insider, host Neal Bhatia, MD speaks with practice management experts about the complex inner workings of an office environment, as well as the role of physicians in managing precarious situations regarding employees. Offering advice for maneuvering these situations, guests SMerz Acquires Ulthera; Ulthera Gets Decolletage Indication, and a New Topical for Onychomycosis
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-merz-acquires-ulthera-ulthera-gets-decolletage-indication-and-a-new-topical-for-onychomycosis/19117/In this edition of DermWireTV, from the publishers of Practical Dermatology® magazine, learn the latest on the Merz/Ulthera acquisition, a new topical for toenail fungus, and FDA accepts Kythera's NDA.Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
https://practicaldermatology.com/series/dermwire-tv/fda-approves-new-drug-prurigo-nodularis-long-term-use-dupilumab-examined/26925/In this week's DermwireTV, the FDA approves Galderma's Nemluvio for adults with prurigo nodularis; a study examines the long-term use of dupilumab for atopic dermatitis; and Andrew Mastro discusses how to talk to patients about starting a Janus kinase (JAK) inhibitor for AD.On New Therapeutics and Real Sushi
https://practicaldermatology.com/series/the-practical-dermatology-podcast/on-new-therapeutics-and-real-sushi/32849/The latest news and updates, plus E. James Song, MD, FAAD, joins Practical Dermatology Associate Medical Editor Lisa Swanson, MD, FAAD, to discuss the 2025 outlook for new therapeutics and play "Two Truths and a Lie." Dr. Song says he has been a wrestler, a jazz musician, and a sushi cheNew Analysis of Benzene Contamination in BPO Products
https://practicaldermatology.com/series/dermwire-tv/new-analysis-benzene-contamination-bpo-products/29074/In this week's DermwireTV, new data continues to raise concerns about benzene contamination in BPO products; the FDA expands the approved dosage for Ameluz for actinic keratosis (AK); and in our PA Perspectives segment, Andrew Mastro discusses how to approach a contract negotiation.Noah Worcester 2024: Dr. Bhatia on Actinic Keratosis
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-bhatia-actinic-keratosis/24585/Neal Bhatia, MD, FAAD, summarizes his lecture on actinic keratosis and photodynamic therapy at the 2024 Noah Worcester Dermatological Society meeting.New Drugs Helping AD Catch Up to Psoriasis
https://practicaldermatology.com/series/updates-atopic-dermatitis/new-drugs-helping-ad-catch-psoriasis/28650/Dr. H.L. Greenberg, a board-certified dermatologist and founder of Las Vegas Dermatology®, talks with Practical Dermatology about some of the new drugs that are helping atopic dermatitis catch up to psoriasis in terms of available therapeutics.